DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December: Citi Global Healthcare Conference (Miami)Date:Tuesday, December 2, 2025Time:1:00 pm ETFormat:Fireside ChatWebcast:FTRE Citi webcast Evercore 8th Annual Healthca ...

Madison Investments, an investment advisor, released its “Madison Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The third quarter was difficult for the Small Cap Fund.  The small-cap index’s performance was broad-based. The Madison Small Cap Fund (class Y) was down 1.3% in the quarter, significantly underperforming the benchmarks. The underperformance was driven by stock selection and exacerbated by a very speculative market. In addition, please check the f ...

DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender Offer”) described in the Offer to Purchase dated October 20, 2025 by purchasing $75,743,000 in aggregate of the Company’s outstanding 7.500% Senior Secured Notes due 2030 (CUSIP No. 34965K AA5 (Rule 144A); U31685 AA5 (Reg S)) (each, a “Note” and collectively, the “Notes”). The Tender Offer to re ...

WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, on Wednesday, December 3, 2025, after the close of the stock market. The Company will h ...

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) is a contract research organization. It provides drug discovery, non-clinical development, and safety testing services. With a market cap of approximately $8 billion, Charles Rivers operates through Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions segments. The healthcare major has notably underperformed the broader market over the past year. CRL stock prices have decl ...

Shares of Inotiv, Inc. (NOTV) jumped more than 23% in overnight trading after the company released preliminary results for its fiscal fourth quarter and full year ended September 30, 2025.The Indiana-based contract research organization, known for its nonclinical drug discovery and development services, expects Q4, 2025 revenue in the range of $137.5 million to $138.5 million, compared to $130.4 million in the prior year's fourth quarter - an increase of roughly 6% year-over-year.For the full fiscal year 2 ...

Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million Updated Time of Company Presentation at Jefferies Global Healthcare Conference WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and s ...

Core Insights - Velocity Clinical Research has appointed Andrew (Drew) Reina as Chief Revenue Officer, effective immediately, to enhance its strategic partnerships and revenue growth [1][2][3] Company Overview - Velocity is a leading integrated site organization for clinical trials, operating over 70 sites with more than 200 investigators, partnering with pharmaceutical and biotechnology companies [7] - The company aims to set the standard for strategic relationships between multisite clinical research corporations, Sponsors, and CRO partners [2] Leadership and Experience - Drew Reina brings over two decades of global clinical research experience, previously serving as Vice President and Head of Sales at Fortrea, where he led a high-performing commercial organization [4][5] - His experience includes overseeing a $1 billion+ global portfolio at PPD's Biopharma segment, focusing on strategic partnerships and alliance management [5] Strategic Goals - As CRO, Drew will drive growth through strategic partnerships with Sponsors and CROs, aligning business development, marketing, and network operations to ensure consistent revenue performance [6] - The organization is positioned to meet the evolving needs of clinical research, helping to accelerate speed to market and alleviate burdens on sites and patients [4][6] Technological Advancements - Velocity operates a technology hub in India, developing innovative systems to leverage expansive site, patient, and historical performance data, enhancing efficiency in clinical trials [8]

Financial Performance & Strategic Review - Charles River's Board supports the company's strategic direction, focusing on strengthening its scientific portfolio, divesting underperforming assets, maximizing financial performance, and maintaining disciplined capital deployment[7] - The company is refining its portfolio by selling certain underperforming or non-core businesses, representing approximately 7% of the estimated 2025 revenue[9] - These divestitures are expected to result in non-GAAP earnings per share accretion of at least $0.30 on an annualized basis once completed, excluding reinvestment benefits or interest expense impacts[9] - A new $1.0 billion stock repurchase authorization was approved by the Board in October, replacing a previous authorization under which $450.7 million in common stock had been repurchased since August 2024[10] 3Q25 Results & Updated Guidance - 3Q25 revenue was $1,004.9 million, a 0.5% decrease compared to $1,009.8 million in 3Q24, with a 1.6% organic revenue decline[13] - The GAAP EPS for 3Q25 was $1.10, a 17.3% decrease from $1.33 in 3Q24, while the non-GAAP EPS was $2.43, a 6.2% decrease from $2.59[15] - The company revised its 2025 revenue growth guidance to a decline of 1.5%-0.5% reported and a decline of 2.5%-1.5% organic[16] - The 2025 non-GAAP EPS estimate is now $10.10-$10.30, which includes a $0.10 guidance improvement at the midpoint[36] Segment Performance & Outlook - DSA (Discovery and Safety Assessment) revenue for 3Q25 was $600.7 million, a 2.3% decrease compared to $615.1 million in 3Q24, with a 3.1% organic revenue decline[17] - RMS (Research Models and Services) revenue for 3Q25 was $213.5 million, a 7.9% increase compared to $197.8 million in 3Q24, with a 6.5% organic revenue growth[25] - Manufacturing revenue for 3Q25 was $190.7 million, a 3.1% decrease compared to $196.9 million in 3Q24, with a 5.1% organic revenue decline[28]

Core Insights - Charles River Laboratories raised its annual profit forecast following strong third-quarter results, driven by stabilized demand in drug discovery and development services [1] Financial Performance - The company reported robust third-quarter results, indicating a positive trend in its financial performance [1] - The updated profit forecast reflects confidence in continued demand for its services [1] Market Demand - Stabilized demand for drug discovery and development services has contributed significantly to the company's performance [1]